MALT1 tumor suppressant, pharmaceuticals containing the same, and use

MALT1 tumor inhibitors targeting the death domain of the MALT1 protein disrupt the CARMA3-BCL10-MALT1 complex, providing effective treatment for both hematological and solid tumors by inhibiting the complex's activity and inducing immune responses.

JP2026519616APending Publication Date: 2026-06-16XZYP (BEIJING) BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
XZYP (BEIJING) BIOTECH CO LTD
Filing Date
2024-06-03
Publication Date
2026-06-16

AI Technical Summary

Technical Problem

Existing MALT1 inhibitors primarily target the Para-caspase fragment of the MALT1 protein, which are effective against hematological tumors but lack efficacy in treating solid tumors, and there is a need for inhibitors that can disrupt the CARMA3-BCL10-MALT1 complex to treat a broader range of cancers.

Method used

Development of MALT1 tumor inhibitors that target the death domain of the MALT1 protein, specifically the MALT1 tumor effect region, to disrupt the CARMA3-BCL10-MALT1 complex, combined with conventional Para-caspase inhibitors, for treating both hematological and solid tumors.

Benefits of technology

The MALT1 tumor inhibitors effectively suppress the activity of the CARMA3-BCL10-MALT1 complex, leading to significant therapeutic effects on various cancers, including solid tumors, by inhibiting tumor growth and inducing immune responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026519616000031
    Figure 2026519616000031
  • Figure 2026519616000032
    Figure 2026519616000032
  • Figure 2026519616000033
    Figure 2026519616000033
Patent Text Reader

Abstract

The present invention provides a MALT1 tumor suppressor that can suppress the expression of the MALT1 gene or inactivate the function of the MALT1 protein, and the MALT1 tumor suppressor is selected from the group consisting of a preparation that affects the expression of the death region of the MALT1 protein, a preparation that knocks out the death region, a preparation that alters the structure of the death region, or a preparation that degrades the death region. The MALT1 tumor suppressor can effectively treat a large number of solid tumors and can treat tumors that cannot be treated with immune checkpoint suppressors, and furthermore, when the MALT1 tumor suppressor is used in combination with an immune checkpoint suppressor, it can act synergistically, and the therapeutic effect is significantly enhanced.
Need to check novelty before this filing date? Find Prior Art